Tag Archives: Clovis Oncology

The President & CEO of Clovis Oncology (NASDAQ: CLVS) is Buying Shares

Today, the President & CEO of Clovis Oncology (CLVS – Research Report), Patrick Mahaffy, bought shares of CLVS for $279.6K. Following this transaction Patrick Mahaffy’s holding in the company was increased by 5.74% to a total of $5.18 million. In

A Director at Clovis Oncology (NASDAQ: CLVS) is Buying Shares

Today, a Director at Clovis Oncology (CLVS – Research Report), Thorlef Spickschen, bought shares of CLVS for $50.23K. This recent transaction increases Thorlef Spickschen’s holding in the company by 22.79% to a total of $264.7K. In addition to Thorlef Spickschen,

Clovis Oncology (CLVS) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology (CLVS – Research Report), with a price target of $36. The company’s shares closed yesterday at $8.87, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: Clovis Oncology (NASDAQ: CLVS) and Unum Therapeutics Inc (NASDAQ: UMRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clovis Oncology (CLVS – Research Report) and Unum Therapeutics Inc (UMRX – Research Report) with bullish sentiments. Clovis Oncology (CLVS) In a

Analysts Offer Insights on Healthcare Companies: Clovis Oncology (NASDAQ: CLVS), CytomX Therapeutics Inc (NASDAQ: CTMX) and Aslan Pharmaceuticals Ltd (NASDAQ: ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clovis Oncology (CLVS – Research Report), CytomX Therapeutics Inc (CTMX – Research Report) and Aslan Pharmaceuticals Ltd (ASLN – Research Report) with

J.P. Morgan Keeps a Hold Rating on Clovis Oncology (CLVS)

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Clovis Oncology (CLVS – Research Report), with a price target of $27. The company’s shares closed on Friday at $14.78, close to its 52-week low